Results 251 to 260 of about 376,206 (315)

Human Leukocyte Elastase Triggered Nanoparticles for Targeted Antimicrobial Delivery and Oral Microbial Modulation

Advanced NanoBiomed Research, EarlyView.
This study explores enzyme‐responsive nanoparticles for targeted antimicrobial release in inflamed oral environments. Nanoparticles formed by complexing peptides and chlorhexidine respond to human leukocyte elastase and release chlorhexidine selectively. P7 (ECAAPVCE)‐based formulations show optimal properties and stability, with antimicrobial activity
Mohammed A. Hadis, Ignacio Insua, Farah N. S. Raja, Álvaro Vila, William M. Palin, Michael R. Milward, Paul R. Cooper, Sarah A. Kuehne, Owen Addison, Paco Fernandez‐Trillo   +9 more
wiley   +1 more source

Significance of RGS13 expression in lupus B cells. [PDF]

PLoS One
Nakajima T, Kitagori K, Funakoshi S, Shirakashi M, Hiwa R, Tsuji H, Akizuki S, Nakashima R, Morinobu A, Yoshifuji H.   +9 more
europepmc   +1 more source

Antibacterial consumption in public health facilities in Uganda: a trend analysis of national warehouse distribution data 2022-2024. [PDF]

JAC Antimicrob Resist
Nsubuga B, Chelimo VM, Kayemba A, Ampaire P, Nambatya W, Rajab K, Twemanye V, Akello H, Ddamba A, Kamabare M, Arinaitwe D, Kakooza F, Walwema R.   +12 more
europepmc   +1 more source

Directly comparing randomized and real-world controls in adjuvant breast cancer. [PDF]

J Comp Eff Res
Walker B, Boyd M, Silver M, Shi J, Bulsara P, Balanchivadze N, Robert NJ.   +6 more
europepmc   +1 more source

PEG Alternatives in Liposomal Nanocarriers: Physicochemical Characteristics and Sustainable Process Strategies

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT The global trend toward sustainable and intensified bioprocesses is driving innovation in the design and scalable synthesis of liposomal nanocarriers, a cornerstone of modern drug delivery. For decades, these nanosystems have relied exclusively on polyethylene glycol (PEG) for their sustained circulation in vivo, but they are currently ...
Chandra Has
wiley   +1 more source

Caregiver-perceived behavioral challenges in fragile X syndrome and implications for measuring treatment benefit in clinical trials. [PDF]

J Patient Rep Outcomes
Merikle E, Tich N, Sebree T, Hagerman R, O'Quinn S, Nomikos G, Bzdek K.   +6 more
europepmc   +1 more source

Clinical Trial Designs for Rare Disorders: A Scoping Review of the Effectiveness of Pharmacologic Interventions in Fragile X Syndrome. [PDF]

Neurol Genet
Van Steenbergen A, Kaur M, Rubanarayana K, Bolduc F.   +3 more
europepmc   +1 more source

A hybrid feature selection framework combining Artificial Bee Colony and decision trees for CVD risk assessment. [PDF]

Sci Rep
Pavithra V, Raja JE, Patil S.
europepmc   +1 more source

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance. [PDF]

Adv Ther
Sebata A, Nagao T, Matsukawa T, Maeno Y, Suzuki M, Yoshikawa Y, Ibe S, Fukuda A, Wang D.   +8 more
europepmc   +1 more source